Erasca updates ERAS-0015 data, plans registration-enabling trials, reports Q2 2026 results

Erasca, Inc. reported updated clinical data and financial results for the quarter ended June 30, 2026 on August 11, 2026.

In July 2026, the company announced updated preliminary data from the ongoing AURORAS-1 Phase 1 trial in the U.S., building on an April 2026 announcement, with additional patients enrolled and more follow-up time.¹ At the recommended dose for expansion of 32 mg once daily, ERAS-0015 showed a 57% uORR8wk in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, with ongoing treatment across all responding patients and most enrolled patients. Tolerability remained favorable, with mostly low-grade treatment-related adverse events, no dose-limiting toxicities, no patients stopping treatment due to drug-related effects, and dose intensity holding at 100% of the target level at both the 24 mg and 32 mg doses.¹ The company also cleared the first dose escalation cohort of ERAS-0015 (16 mg) in combination with the approved dose of panitumumab with no dose-limiting toxicities, and continues backfill enrollment in that cohort while escalating the 24 mg combination cohort.¹

Also in July 2026, Erasca said it plans to move ERAS-0015 into potentially registration-enabling development in pancreatic and lung cancers.¹ Per the release's milestone table, the company expects Phase 1 monotherapy expansion data and combination dose escalation data, including the panitumumab combination, in the first half of 2027, initiation of a potentially registration-enabling trial in second-line or later NSCLC in the first half of 2027, a Phase 3 pivotal trial in first-line PDAC starting in 2027, and a Phase 3 pivotal trial in RAS-mutant NSCLC starting between the second half of 2027 and first half of 2028.¹ For ERAS-4001, the company expects preliminary Phase 1 monotherapy data in the second half of 2026, with expansion and combination cohorts planned for 2027.¹

On the balance sheet, Erasca held $384.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, versus $341.8 million at the end of 2025.¹ In July 2026 the company completed an upsized public offering that raised approximately $632.5 million in gross proceeds.¹ Erasca said it expects its current cash position, including net proceeds from the July offering, to be sufficient to fund the milestones listed in the release.¹